<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958382</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-IIT-01</org_study_id>
    <nct_id>NCT04958382</nct_id>
  </id_info>
  <brief_title>Study for Evaluating the Efficacy of Ciprofol in Patients Under Narcotic Sleep With Chronic Insomnia</brief_title>
  <official_title>A Single Center, Randomized, Single Blind, Exploratory Study for Evaluating the Efficacy of Ciprofol in Patients Under Narcotic Sleep With Chronic Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, single blind, exploratory clinical study.About 30&#xD;
      patients with chronic insomnia are planned to be enrolled in this study and randomized into&#xD;
      two groups by a ratio of 4:1 (Figure 1), with group 1 (24 subjects) for ciprofol and group 2&#xD;
      (6 subjects) for placebo (fat emulsion). Cognitive behavioral therapy (CBT) will be given to&#xD;
      these patients during the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnography (PSG)</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>total sleep time (TST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography (PSG)</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>sleep latency (SL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography (PSG)</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>wake after sleep onset (WASO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep log</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>subjective total sleep time (sTST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep log</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>subjective sleep-onset latency (sSOL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep log</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>subjective wake after sleep onset (sWASO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-rating scales</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating scales</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>Insomnia Severity Index (ISI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating scales</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>PHQ-9 Depression Test Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating scales</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>GAD-7 Anxiety Test Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating scales</measure>
    <time_frame>Day -2 to Day 90</time_frame>
    <description>Epworth Somnolence Scale;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Insomnia</condition>
  <arm_group>
    <arm_group_label>Ciprofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofol</intervention_name>
    <description>intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance</description>
    <arm_group_label>Ciprofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medium/long chain fat emulsion injection (C8-24Ve)</intervention_name>
    <description>at the infusion rate of 25-30 mL/h</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 (inclusive) to 70 (inclusive) years old;&#xD;
&#xD;
          2. ASA class of I-II;&#xD;
&#xD;
          3. With chronic insomnia refractory to conventional drugs in the past 3 months&#xD;
             (benzodiazepine receptor agonists and other drugs). Other drugs: melatonin, melatonin&#xD;
             receptor agonists, and traditional Chinese medicine;&#xD;
&#xD;
          4. Compliant with the diagnostic criteria of ICSD-3 chronic insomnia:&#xD;
&#xD;
               1. At least one of the following chief complaints: initial insomnia, difficulty in&#xD;
                  sleep maintenance, early awakening, refusal to go to bed at an appropriate time,&#xD;
                  and difficulty in falling asleep without nursing;&#xD;
&#xD;
               2. At least one of the following daytime symptoms: tiredness, short tempered,&#xD;
                  work/study/social skills decreased;&#xD;
&#xD;
               3. Occurrence of the above symptoms at least 3 times per week and lasting for more&#xD;
                  than 3 months;&#xD;
&#xD;
          5. Voluntarily adopt narcotic sleep and obtain the written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With contraindications to deep sedation/general anesthesia or a history of past&#xD;
             sedation/anesthesia accidents;&#xD;
&#xD;
          2. With a history of allergy or contraindications to anesthetics;&#xD;
&#xD;
          3. With a medical history or evidence of any of the followings before screening/at&#xD;
             baseline, which may increase sedation/anesthesia risks:&#xD;
&#xD;
               1. History of cardiovascular diseases: uncontrolled hypertension [systolic blood&#xD;
                  pressure (SBP) ≥ 170 mmHg and/or diastolic blood pressure (DBP) ≥ 105 mmHg&#xD;
                  without treatment, or SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg despite&#xD;
                  antihypertensive treatment], severe arrhythmia, heart failure, Adams-stokes&#xD;
                  syndrome, New York Heart Association (NYHA) Class ≥ III, severe superior vena&#xD;
                  cava syndrome, pericardial effusion, acute myocardial ischemia, unstable angina,&#xD;
                  myocardial infarction within 6 months before screening, history of&#xD;
                  tachycardia/bradycardia requiring medical treatment, II-III degree&#xD;
                  atrioventricular block (excluding patients with pacemakers);&#xD;
&#xD;
               2. History of respiratory system disorders: respiratory insufficiency, history of&#xD;
                  obstructive pulmonary disease, history of bronchospasm requiring treatment within&#xD;
                  3 months before screening, and acute respiratory tract infection with obvious&#xD;
                  symptoms such as fever, wheezing, nasal obstruction, and cough within 1 week&#xD;
                  before baseline;&#xD;
&#xD;
               3. History of neurological and psychiatric disorders: craniocerebral injury,&#xD;
                  possible convulsions, myoclonus, intracranial hypertension, cerebral aneurysms,&#xD;
                  history of cerebrovascular accidents; schizophrenia, mania, insanity, history of&#xD;
                  cognitive disorder; history of epilepsy; mental disorder suggested by Mini&#xD;
                  International Neuropsychiatric Interview (MINI);&#xD;
&#xD;
               4. History of gastrointestinal disorders: gastrointestinal retention, active&#xD;
                  hemorrhage, or conditions that may lead to reflux and aspiration;&#xD;
&#xD;
               5. History of blood donation or blood loss of ≥ 400 mL within 3 months before&#xD;
                  screening;&#xD;
&#xD;
          4. With the following airway management risks at screening:&#xD;
&#xD;
               1. History of asthma or stridor;&#xD;
&#xD;
               2. Sleep apnea syndrome;&#xD;
&#xD;
               3. History or family history of malignant hyperthermia;&#xD;
&#xD;
               4. History of tracheal intubation failure;&#xD;
&#xD;
               5. Judged by investigators to have difficult airway or judged as difficult tracheal&#xD;
                  intubation (modified Mallampati class IV) at screening;&#xD;
&#xD;
          5. Receipt of any of the following medications/therapies at screening/baseline:&#xD;
&#xD;
               1. Any clinical study within 1 month before screening;&#xD;
&#xD;
               2. Sedatives/anesthetics, and/or sedative-hypnotics within 72 h before baseline;&#xD;
&#xD;
               3. Antidepressants and anxiolytics within 14 days before baseline;&#xD;
&#xD;
          6. Laboratory test abnormalities at screening:&#xD;
&#xD;
               1. Total bilirubin &gt; 2 × ULN (upper limit of normal);&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine transaminase (ALT) &gt; 2 × ULN;&#xD;
&#xD;
               3. Blood creatinine &gt; 1.5 × ULN;&#xD;
&#xD;
          7. Unable to fast for 6 h before dose administration;&#xD;
&#xD;
          8. With a history of smoking, drug abuse and/or positive urine drug screening results, or&#xD;
             positive breath alcohol test results at baseline and/or a history of alcohol abuse&#xD;
             within 3 months before screening. Alcohol abuse is defined as an average of &gt; 2 units&#xD;
             of alcohol consumed per day (1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor&#xD;
             with 40% alcohol, or 150 mL of wine);&#xD;
&#xD;
          9. Pregnant or breastfeeding females; women of child-bearing potential or men who are&#xD;
             unwilling to use contraception during the trial; or patients who are planning&#xD;
             pregnancy within 1 month after the trial (including male patients);&#xD;
&#xD;
         10. Unable to avoid engaging in dangerous occupations requiring concentration and/or motor&#xD;
             coordination 72 h after administration;&#xD;
&#xD;
         11. Judged by investigators to be unsuitable for participating in this trial for any&#xD;
             reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Mengchang Yang</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

